Shanghai Kaibao Pharmaceutical Sales Co., Ltd. announced that it expects to receive CNY 20 million in funding from Shanghai Kaibao Pharmaceutical CO.,Ltd
December 09, 2020
Share
Shanghai Kaibao Pharmaceutical Sales Co., Ltd. announced that it will issue common share for the gross proceeds of CNY 20 million on December 10, 2021. The transaction will include participation from existing investor, Shanghai Kaibao Pharmaceutical CO.,Ltd (SZSE:300039). Post completion, the investor will retain 100% stakes in the company and registered capital of the company will increase to CNY 30 million. The transaction has been approved by first meeting of the fifth board of directors of Shanghai Kaibao Pharmaceutical CO.,Ltd (SZSE:300039) and does not need to be submitted to the general meeting of shareholders.
Shanghai Kaibao Pharmaceutical CO.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The Company's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The Company's products include injections, tablets, capsules, granules, vinum and pills, among others. The Company distributes its products in domestic markets.
Shanghai Kaibao Pharmaceutical Sales Co., Ltd. announced that it expects to receive CNY 20 million in funding from Shanghai Kaibao Pharmaceutical CO.,Ltd